virtual CROI 2021 Schedule at a Glance Version 3 (Short)

LIVE PROGRAM

TIME SATURDAY, MARCH 6, 2021 SUNDAY, MARCH 7, 2021

10:00 AM W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES OPENING SESSION (10:00 – 12:05) EST (10:00 – 14:00) CHAIRS WELCOME TO virtual CROI 2021 START Conveners: Serena S. Spudich and Nicolas Chomont Chairs: Sharon L. Hillier, James A. Hoxie, and Elaine J. Abrams  ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 MARTIN DELANEY PRESENTATION

LIVE PROGRAM LIVE Frank Kirchhoff  INTRODUCTION  ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY James Pickett Galit Alter  VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-CoV-2 VACCINES WILL PERPETUATE THE PANDEMIC  ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC Gregg S. Gonsalves and Fatima Hassan Jürgen Rockstroh BERNARD FIELDS LECTURE  ADVANCES IN BIOMEDICAL PREVENTION OF HIV  INTRODUCTION Jean-Michel Molina James A. Hoxie and Galit Alter  ADVANCES IN HIV CURE  NEUTRALIZING AGAINST CORONAVIRUSES Katherine J. Bar Pamela J. Bjorkman N'GALY-MANN LECTURE  INTRODUCTION Elaine J. Abrams and Tedros Adhanom Ghebreyesus  LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET Anthony S. Fauci

12:20 PM CONCURRENT WORKSHOPS (12:20 – 2:20) EST W-2 FRONTIERS IN LABORATORY TECHNOLOGIES

Conveners: Galit Alter and Frank Kirchhoff  STRUCTURES OF SARS-CoV-2 ANTIBODIES INDUCED BY INFECTION AND mRNA VACCINES Christopher O. Barnes

 EMERGING CONCEPTS IN HIV-1 RESTRICTION

Edward Campbell  SARS-CoV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES Daniela Weiskopf

 ARTIFICIAL INTELLIGENCE-INSPIRED ENGINEERING Sai Reddy W-3 CLINICAL TRIAL DESIGN AND ANALYSIS

Conveners: Susan P. Buchbinder and Richard E. Chaisson  MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS Lori Dodd  DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS Holly Janes W-4 CASE TRACING AND CASE MANAGEMENT: COVID-19 WORKSHOP Conveners: Robert T. Schooley and David L. Thomas  RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19 Kwok-Yung Yuen  COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS Sanjay Bhagani  CRITICAL CARE OF COVID-19 Janhavi Athale

LIVE PROGRAM Last Updated on March 4, 2021 LIVE PROGRAM TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2021 WEDNESDAY, MARCH 10, 2021

10:00 PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) AM EST Session Hosts: Wesley Sundquist and Carlos del Rio Session Hosts: Peter W. Hunt and Sharon L. Hillier Session Hosts: Nicolas Chomont and Elaine J. Abrams START WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP Sharon L. Hillier Elaine J. Abrams James A. Hoxie P-1 IMAGING VIRAL LIFE CYCLES P-3 HIV-1 bNAbs: LOOKING AHEAD P-5 ELITE CONTROLLERS: A MODEL FOR A FUNCTIONAL CURE OF HIV-1 INFECTION Hans-Georg Kräusslich Marina Caskey Xu Yu P-2 DISPARITIES IN HEALTH: FROM HIV TO COVID-19 AND BEYOND P-4 SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV P-6 HIV TREATMENT IN PREGNANCY: BEYOND PREVENTION OF VERTICAL TRANSMISSION James E. Hildreth Linda-Gail Beker Shahin Lockman

LIVE PROGRAM LIVE

11:15 AM CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) EST O-1 HIV/SIV HOST AND CELLULAR INTERCTIONS: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-5 SARS-CoV-2 VS HOST: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-10 HIV RESERVOIRS Oral Abstract Moderators: John M. Coffin and Richard A. Koup Oral Abstract Moderators: Wesley I. Sundquist and Guido Silvestri Oral Abstract Moderators: Douglas D. Richman and Katharine J. Bar  DECIPHERING THE HOST NUCLEUS SUBVERSION BY HIV-1 TO REPLICATE  IFITM PROTEINS PROMOTE SARS-CoV-2 INFECTION IN HUMAN LUNG CELLS  INFECTED CELLS ARE CLONOTYPICALLY DIVERSE IN BLOOD & LYMPH NODES SINCE FIEBIG STAGE I Francesca Di Nunzio Caterina Prelli Bozzo Pierre Gantner  HIV-1 CAPSID RETAINS ITS INTEGRITY UNTIL MINUTES BEFORE UNCOATING IN THE NUCLEUS  SARBECOVIRUS ORF6 PROTEINS ANTAGONIZE INTERFERON SIGNALING  EVOLUTIONARY DYNAMICS OF HIV RESERVOIR CELLS VIA A NOVEL SINGLE-CELL MULTIOMICS ASSAY Chenglei Li Izumi Kimura Kevin B. Einkauf  TRAFFICKING OF HIV-1 ENVELOPE TO THE EHD1/MICAL-L1 TUBULAR-SORTING ENDOSOME  SEVERE COVID-19 IS FUELED BY DISRUPTED GUT BARRIER INTEGRITY  NONINVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POSTTREATMENT HIV CONTROL Paul Spearman Leila B. Giron Leila B. Giron  A COMPREHENSIVE CRISPR SCREEN FOR HIV DEPENDENCY FACTORS  SARS-CoV-2 PERSISTS IN INTESTINAL ENTEROCYTES UP TO 7 MONTHS AFTER SYMPTOM RESOLUTION  PD-1 BLOCKADE ENHANCES THERAPEUTIC BENEFITS OF VACCINE IN A CHRONIC SIV/MACAQUE MODEL Vanessa R. Montoya Minami Tokuyama Sheikh A. Rahman  EARLY bNAb THERAPY IN SHIVAD8-EO–INFECTED RHESUS MACAQUES  COVID-19 OUTCOME: INSIGHTS FROM QUANTIFICATION OF VIREMIA AND  TYPE I INTERFERON-ASSOCIATED GENE EXPRESSION PREDICTS TIME TO VIRAL REBOUND ON TI Joana Dias Penny Zacharopoulou  IMMUNE CORRELATES OF POSTTREATMENT CONTROL IN SHIV-INFECTED INFANT MACAQUES Jana L. Jacobs Veronica Obregon-Perko  CHARACTERIZATION AND EPITOPE MAPPING OF SARS-CoV-2–SPECIFIC T CELLS  HIV-1 PROVIRUS CANNOT BE REACTIVATED IN PATIENTS ON TREATMENT WITH ART AND DASATINIB  SIV∆GY INFECTION INDUCES ELITE CONTROL AND RESISTANCE TO SHIV HETEROLOGOUS CHALLENGE Kristin L. Boswell Mayte Coiras Susan Pereira Ribeiro  BARICITINIB LOWERS INFLAMMATION AND PATHOLOGY IN SARS-CoV-2–INFECTED RHESUS MACAQUES  DURABLE HIV-1 ANTIBODY PRODUCTION IN HUMANS AFTER AAV8-MEDIATED GENE TRANSFER  TRAPPING THE HIV-1 V3 LOOP IN A HELICAL CONFORMATION ENABLES BROAD NEUTRALIZATION Timothy Hoang Joseph P. Casazza Matthias Glögl  ONE DOSE OF COVID-19 mRNA VACCINE IN SARS-CoV-2–EXPERIENCED PEOPLE MAY BE SUFFICIENT  A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION  AN Env-gag mRNA VACCINE PROTECTS MACAQUES FROM HETEROLOGOUS TIER-2 SHIV INFECTION Mark Mulligan Beatriz Mothe Peng Zhang  SARS-CoV-2 RECRUITS A HAEM METABOLITE TO EVADE ANTIBODY IMMUNITY O-11 BRAIN CONNECTIONS, MALIGNANCIES, AND TUMOR VIRUSES O-2 HIV TREATMENT AND PREVENTION: NEW OPPORTUNITIES TO OPTIMIZE DRUG DOSING, ADHERENCE, AND Annachiara Rosa Oral Abstract Moderators: Dennis L. Kolson and Ronald T. Mitsuyasu ANTIRETROVIRAL THERAPY O-6 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV  NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART Oral Abstract Moderators: Angela Kashuba and Courtney V. Fletcher Oral Abstract Moderators: Kazuo Suzuki  ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP Joseph J. Eron and Douglas D. Richman  3T BRAIN MRS REVEALS DISTINCT METABOLITE PATTERNS OF ART INITIATION DURING ACUTE HIV Munjal Patel  BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING Napapon Sailasuta  NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS Myron S. Cohen  EFFECTS OF HIV AND AGING ON FUNCTIONAL CONNECTIVITY AND ANATOMY Randolph P. Matthews  BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS Patrick H. Luckett  CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS Michael Dougan  DIVERGENT AND SELF-REACTIVE IMMUNE RESPONSES IN THE CNS OF COVID-19 PATIENTS Justin Lutz  CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS Shelli F. Farhadian  PK AND SAFETY OF HIGH-DOSE IN TB/HIV COINFECTED PATIENTS ON EFV OR DTG Meagan P. O'Brien  CHROMOSOMAL COPY NUMBER ALTERATIONS IN ANAL PRECANCERS FROM PEOPLE WITH HIV Christine Sekaggya-Wiltshire  POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL Tinaye Mutetwa  PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH EFV-BASED ART IN ACTG 5375 Carlijn Jordans  POMALIDOMIDE AND LIPOSOMAL DOXORUBICIN FOR KAPOSI SARCOMA +/– OTHER KSHV DISEASES Kimberly K. Scarsi  ESTIMATING WITHIN-HOST R0 FOR SARS-CoV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY Ramya Ramaswami  EMTRICITABINE TRIPHOSPHATE IN DRIED BLOOD SPOTS PREDICTS FUTURE VIREMIA IN PWH Ruian Ke  VAGINAL pH PREDICTS CERVICAL INTRAEPITHELIAL NEOPLASIA-2 REGRESSION IN HIV+ WOMEN Jose R. Castillo-Mancilla  PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 Katherine G. Michel  TENOFOVIR DIPHOSPHATE TO PREDICT FUTURE VIRAEMIA IN POSTPARTUM WOMEN LIVING WITH HIV Christoph Spinner  WILMS' TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13 Jasantha Odayar  POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH Ayana Morales  NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: 48WKS PRIMARY OUTCOME Sorana Segal-Maurer  INFLAMMASOME ACTIVATION IN PATIENTS WITH KSHV-ASSOCIATED DISORDERS Nicholas Paton  ACTIVITY AND RESISTANCE HARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR Ramya Ramaswami  RANDOMIZED TRIAL OF RESISTANCE TESTING FOR VIROLOGIC FAILURE IN SUB-SAHARAN AFRICA Laurie VanderVeen O-12 MATERNAL AND CHILD HIV AND SARS-CoV-2 Mark Siedner  RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT Oral Abstract Moderators: Landon Myer and Hermione Lyall O-3 COMPLICATIONS OF HIV AND COVID-19 Tracy L. Diamond  COVID-19 INFECTION IN HIGH-RISK SOUTH AFRICAN PREGNANCIES WITH AND WITHOUT HIV Oral Abstract Moderators: Judith S. Currier and Peter W. Hunt O-7 AND HEPATITIS Liesl De Waard  SHORT-COURSE ALENDRONATE FOR THE PREVENTION OF ART-ASSOCIATED BONE LOSS Oral Abstract Moderators:  CHARACTERISATION OF SARS-CoV-2–INFECTED CHILDREN DEVELOPING NEUTRALISING ANTIBODIES Tara McGinty Constance A. Benson and Robert T. Schooley Alessandra Ruggiero  PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV  RIFAPENTINE +/– MOXIFLOXACIN FOR PULMONARY TUBERCULOSIS IN PEOPLE WITH HIV  PEDIATRIC AND ADOLESCENT HIV TESTING AND DIAGNOSIS IN THE CONTEXT OF COVID-19 Michael J. Silverberg April Pettit Jessica M. Gross  SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV  HIGH-DOSE RIFAMPICIN FOR HIV-ASSOCIATED TB MENINGITIS: A PHASE II RANDOMISED TRIAL  DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS Samuel R. Schnittman Fiona Cresswell Anna Turkova  IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV  BICTEGRAVIR CONCENTRATIONS AND VIROLOGIC RESPONSES IN PLWH RECEIVING 1HP FOR LTBI  DolPHIN2 FINAL RESULTS DOLUTEGRAVIR VS IN LATE PREGNANCY TO 72W POSTPARTUM Priscilla Hsue Hsin-Yun Sun Thokozile R. Malaba  BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS  A CLUSTER RANDOMIZED TRIAL OF CONTACT TRACING IN HOUSEHOLDS OF INDEX PATIENTS WITH TB  ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010 Padraig McGettrick Neil A. Martinson Risa M. Hoffman  12-YEAR COGNITIVE DECLINE IS ASSOCIATED WITH LUNG DISEASE, DIABETES, AND DEPRESSION  A CLUSTER RANDOMIZED TRIAL OF TARGETED UNIVERSAL TESTING FOR TB IN CLINICS  SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL Scott Letendre Limakatso Lebina Lameck Chinula  MULTIMORBIDITY IN PEOPLE WITH HIV USING ART IN THE US: PROJECTIONS TO 2030  A SIMPLE AND SAFE APPROACH TO HCV TREATMENT: FINDINGS FROM THE A5360 (MINMON) TRIAL  ADVERSE PREGNANCY OUTCOMES AMONG HIV-INFECTED WOMEN EXPOSED TO ISONIAZID IN BRIEF-TB Parastu Kasaie Sunil S. Solomon Amita Gupta  COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US  HEPATOCELLULAR CARCINOMA AND HBV VIREMIA IN HIV/HBV-COINFECTED PERSONS IN NA-ACCORD O-13 INNOVATIONS AND CHALLENGES IN TESTING, PREVENTION, AND CARE Jing Sun H. Nina Kim Oral Abstract Moderators: Jonathan Mermin and Wafaa M. El-Sadr O-4 IDENTIFYING DISPARITIES AND OPPORTUNITIES IN HIV  UPRISING CIRCULATION OF HBV-COMPLEX PROFILES WITH HBsAg VACCINE-ESCAPE MUTATIONS  PrEP USE DURING ACUTE HIV INFECTION IN A COMMUNITY SETTING COMPROMISES HIV DIAGNOSIS Oral Abstract Moderators: Richard E. Chaisson and Adaora Adimora Lorenzo Piermatteo Donn J. Colby  DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018 O-8 COVID EPIDEMIOLOGY AND ITS IMPACT ON HIV CARE AND PREVENTION  A CLUSTER-RANDOMIZED TRIAL OF TRADITIONAL HEALERS DELIVERING HIV TESTING IN UGANDA Jun Li Oral Abstract Moderators: Susan P. Buchbinder and James McIntyre Radhika Sundararajan  GEOGRAPHIC DIFFERENCES IN TIME TO VIRAL SUPPRESSION IN THE DEEP SOUTH, 2012-2019  PHYLOGENETIC ANALYSIS OF THE TIMING OF SARS-CoV-2 INTRODUCTIONS INTO WASHINGTON STATE  HIV SELF-TESTING TO OPTIMIZE FACILITY TESTING: A CLUSTER-RANDOMIZED TRIAL IN MALAWI Aadia Rana Diana M. Tordoff Kathryn Dovel  DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018  FROM TESTING TO MORTALITY: COVID-19 AND THE INVERSE CARE LAW IN SWITZERLAND  COMMUNITY MULTIMONTH ART PROVISION: POOLED ANALYSIS OF 2 CLUSTER-RANDOMIZED TRIALS Kashif Iqbal Julien Riou John Lopes  GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH  SEX/GENDER DIFFERENCES IN TESTING, PRESENTATION, AND OUTCOMES OF SARS-CoV-2 INFECTION  POINT-OF-CARE URINE TENOFOVIR VERSUS SELF-REPORTED ART ADHERENCE IN ROUTINE HIV CARE Cristina Rodriguez-Hart Eileen P. Scully Yolanda Gomba  HIV TRENDS AMONG THE AMERICAN INDIAN/ALASKA NATIVES, 2014-2018  RACIAL DISPARITIES IN COVID-19 POSITIVITY AMONG PEOPLE LIVING WITH HIV IN THE US  RAPID VS SAME-DAY TREATMENT INITIATION FOR PATIENTS WITH TB SYMPTOMS AT HIV DIAGNOSIS Sophie Sembajwe Jessica Y. Islam Nancy Dorvil  LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN—KENYA  HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS  COMMUNITY DISTRIBUTION OF ART DURING CIVIL UNREST AND COVID-19 IN HAITI Matthew L. Romo Ming J. Lee Patrice Joseph  RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC  CHANGES IN HIV TESTING SERVICES AFTER COVID-19 IN 11 SUB-SAHARAN AFRICAN COUNTRIES  RESILIENCE OF HIV ACTIVITIES DURING COVID-19 PANDEMIC AT HEALTH FACILITIES IN AFRICA Peter Mazonson Bakary Drammeh Tiffany G. Harris  FEE FOR HOME DELIVERY AND MONITORING OF ART RAISES VIRAL SUPPRESSION IN SOUTH AFRICA  DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON Ruanne Barnabas Timothy W. Menza

 COVID-19 IMPACT ON INDEX TESTING SERVICES IN 5 HIGH HIV PREVALENCE INDIAN DISTRICTS

Ajay K. Enugu

O-9 PREVENTION 2021

Oral Abstract Moderators: Raphael J. Landovitz and Landon Myer

 IMPACT OF VAGINAL STIs ON bNAb PROTECTION IN MACAQUES

David A. Garber

 PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS

Albert Liu

 INCIDENCE OF HIV INFECTION WITH DAILY OR ON-DEMAND ORAL PrEP WITH TDF/FTC IN FRANCE

Jean-Michel Molina

 IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA Dvora L. Joseph Davey  COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US Anne M. Neilan  SOCIAL NETWORKS PREDICT PrEP UPTAKE IN SEARCH STUDY IN RURAL KENYA AND UGANDA Catherine A. Koss  HSV-2 ACQUISITION IN A RANDOMIZED TRIAL OF CONTRACEPTIVE METHODS AMONG AFRICAN WOMEN Nelly R. Mugo  LABORATORY ANALYSIS OF HIV INFECTIONS IN HPTN 083: INJECTABLE CAB FOR PrEP Raphael J. Landovitz

LIVE PROGRAM Last Updated on March 4, 2021 LIVE PROGRAM LIVE PROGRAM

LIVE PROGRAM

2:30 PM 1:30 PM TIME END EST EST

I I I (1:30 CONCURRENT INTERACTIVE SESSIONS MONDAY, MARCH 8,2021

- - -        

3 CONTACT TRACING IN CONTROLLING EPIDEMICS: IS THE WORTH JUICE THE 2 CASE 1 SARS

SQUEEZE? THERAPY CONTACT TRACING GOESVIRAL:VALUE ETHICSAND OF DIGITAL CONTACT TRACING Matthew Golden CONTACT TRACING FOR HIV AND SEXUALLY INFECTIONS TRANSMITTED Chi THE ROLE OFCONTACT TRACING IN EPIDEMIC CONTROL: FACILITATORS AND BARRIERS Moderator: Panelists: Moderator: Penny Moore TION ANTIBODY IMMUNITY TO SARS Paul Bieniasz SELECTION OFNEUTRALIZATION RESISTANT SARS Jeremy Luban STRUCTURE AND FUNCTION OFSARS Morgane Rolland SARS Bette Korber HIV Moderators: Jeffrey Khan

– - - Chi Udeagu

1 Env AND SARS 2:30) -

- - CoV CoV BASED DISCUSSION ONWEIGHT GAININHIV ANDANTIRETROVIRAL

-

Grace McComsey, Sadaf Farooqi, Jane O Jane Farooqi, Grace McComsey, Sadaf

2 EVOLUTION AT THE POPULATION LEVEL - 2 EVOLUTION IN POPULATIONS AND INDIVIDUALS Peter W.Peter Hunt Wafaa El Wafaa

Katharine J. Bar and John Coffin John and Bar J. Katharine

- CoV - Sadr - 2 SPIKE EVOLUTION: SIMILARITIES ANDDIFFERENCES

- CoV -

2 501Y.V2 THROUGH VACCINATION AND INFEC- - CoV - 2 SPIKEPROTEIN VARIANTS

- CoV ’

Halloran, and Cissy Kotyo - 2 MUTANTS

I I I (1:30 CONCURRENT INTERACTIVE SESSIONS TUESDAY, MARCH 9,2020

        - - -

6 PrEP SCALE 5 FROM DAILY PILLS TO MONTHLY SHOTS FOR HIV PREVENTION AND TREATMENT: CAN EFFICACY BE 4 HIV TRANSLATED INTO EFFECTIVENESS? INFECTION Mark Dybul CHALLENGES TO PrEP SCALE Elizabeth Irungu PrEP IMPLEMENTATION IN SUB Sheena McCormack THE STAGE:SETTING UNAIDS 2030 GOALS AND CURRENT STATE OFTHE EPIDEMIC Nittaya Phanuphak, Charles Flexner, and Hyman Scott Panelists: Moderators: Ignacio Sanz PATHOLOGICAL B CELL ACTIVATION DURING SARS Robert Seder PROGRAMMING DURABLE IMMUNITY Katie Doores LONGITUDINAL ANTIBODY RESPONSES TO SARS Julie McElrath T CELLIMMUNITY IN SARS Andrés Finzi HUMORAL RESPONSES AGAINST THE SARS Moderators: – -

2:30) 1 AND SARS

Francois Venter,Francois

-

UP TO MEET UNAIDS 2030 GOAL: IT JUST ISN'T POSSIBLE

Carlos del Rio and Diane Havlir Diane and Rio del Carlos Silvestri Guido and Alter Galit

- CoV

- 2: DURABILITY OF HOST IMMUNE RESPONSES FROM VACCINATION OR

-

COV - UP - -

SAHARAN AFRICA 2 NATURAL INFECTION AND FOLLOWING VACCINATION

- CoV

- - 2 SPIKE CoV -

CoV - 2 AND EMERGING VARIANTS

- 2 INFECTION

— OR IS IT?

I I I (1:30 CONCURRENT INTERACTIVE SESSIONS WEDNESDAY, MARCH 10, 2020

          - - -

9 COVID 8 COVID 7 SARS Robert E. Fullilove David R.Wilson Mary T. Bassett Moderators: Panelists: Case Presenters and Discussion Moderators: Marcus Buggert Julie Overbaugh Gestur Vidarsson Catherine Blish Benjamin tenOever Nicolas Chomont Moderators: INCARCERATED POPULATIONS AND COVID DISPARITIES IN COVID DISPARITIES IN COVID CASE 2: LONG CASE 1: TREATMENT APPROACHES FOR A PATIENT WITH COVID THE SPECTRUM TCELL OF RESPONSES TO SARS HUMORAL IMMUNE RESPONSES TO SARS AFUCOSYLATED IgG RESPONSES AND SEVERITY IN COVID TOWARDS SWEET THERAP SARS –

2:30) - CoV - CoV - - 19 DISPARITIES: HOW CAN THEY HELP MOVE THE NEEDLE FORWARD? 19 CLINICAL CONTROVERSIES -

Karine Lacombe, Zarir Udwadia, and Claudia Cortes Claudia and Udwadia, Zarir Lacombe, Karine 2 DEBRIS AND ITSCONTRIBUTION TO COVID - 2 AND THE HOST IMMUNE RESPONSE: GOOD VS BAD IMMUNITY Adaora Adimora and Monica Gandhi Monica and Adimora Adaora and Koup A. Richard - TERM OUTCOMES WITH A PATIENT WHORECOVERS FROM COVID

- - 19 IN NATIVE AMERICAN COMMUNITIES 19 AMONG RACIAL AND ETHNIC MINORITIES IN THE US IES FOR SOUR IMMUNOPATHOLOGIES IN COVID

- - COV 19

Roy M. Gulick and Paul E. Sax E. Paul and Gulick M. Roy - - 2 (VIRSCAN) CoV

- 2

- 19 - 19

- 19 INFECTION Last Updatedon March 4,2021

- 19

- 19 INFECTION

ON-DEMAND PROGRAM TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2020 WEDNESDAY, MARCH 10, 2020

SYMPOSIA ARE ON - DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM) ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM) ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM) RELEASED EACH S-1 NAVIGATING TO THE NUCLEUS S-5 IMMUNE-MEDIATING KILLING OF HIV RESERVOIRS: OPPORTUNITIES AND OBSTACLES S-9 NEW FINDINGS AND UNSETTLED CONTROVERSIES IN CENTRAL NERVOUS SYSTEM INFECTION AND DISEASE DAY AT 12:01 Conveners: John M. Coffin and Wesley I. Sundquist Conveners: Nicolas Chomont and Katharine J. Bar Conveners: Dennis L. Kolson and Serena S. Spudich AM EST  LIVE-CELL IMAGING: CAPSID TRAFFICKING TO THE NUCLEUS  HOW TO GENERATE GOOD KILLERS BY INITIATING ART (NOT TOO) EARLY?  NOVEL FINDINGS OF NEURONAL MODULATION OF HIV EXPRESSION IN MICROGLIA Barbara Müller Mark Dybul Jonathan Karn  LIVE-CELL IMAGING OF HIV-1 NUCLEAR IMPORT, UNCOATING, AND PROVIRUSES  BREAKING THE B-CELL FOLLICLE BARRIER TO ELIMINATE VIRAL RESERVOIRS  ROLE OF CNS CD4 T CELLS AND MACROPHAGES IN SIV NEUROPATHOGENESIS AND RESERVOIRS Vanay K. Pathak Afam Okoye Vanessa M. Hirsch  VISUALIZATION OF HIV-1 CAPSID-DEPENDENT REPLICATION IN VITRO  INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING  MYELOID CNS HIV RESERVOIRS...THE DEBATE CONTINUES

Barbie Ganser-Pornillos R. Brad Jones Lishomwa Ndhlovu DEMAND DEMAND PROGRAM -  LENACAPAVIR (GS-6207): FIRST CLINICALLY ACTIVE LONG-ACTING INHIBITOR OF HIV CAPSID  TYPE I INTERFERON RESISTANCE OF REBOUND HIV-1  LESSONS FROM CNS HIV ESCAPE AND ATI FOR UNDERSTANDING HIV PERSISTENCE IN THE CNS Tomas Cihlar Beatrice H. Hahn Sarah B. Joseph ON S-2 INNATE IMMUNE DEFENSES AGAINST HIV-1 AND SARS-CoV-2 S-6 NOVEL ANTIVIRAL STRATEGIES AND HOW TO DEPLOY THEM S-10 ADOLESCENTS, YOUTH, AND PrEP Conveners: Galit Alter and Frank Kirchhoff Conveners: Joseph J. Eron and Huldrych F. Günthard Conveners: Annette H. Sohn and Connie L. Celum  FROM GENOME TO FUNCTION: PHENOTYPIC CHARACTERISATION OF PANDEMIC SARS-CoV-2 VARIANTS  TRIPLE DRUG ART, DUAL ART, OR JUST ART?  PrEP DURING PREGNANCY AND BREASTFEEDING Volker Thiel Jose R. Arribas John Kinuthia  IMMUNE EVASION STRATEGIES BY SARS-CoV-2: Nsp1 AND BEYOND  NOVEL ANTIRETROVIRAL THERAPIES IN CLINICAL DEVELOPMENT  IMPROVING ADOLESCENT PrEP USE: UNDERSTANDING DEVELOPMENTAL PROCESSES AND CONTEXT Konstantin Sparrer Alexandra L. Calmy Claude A. Mellins  SHARED VULNERABILITIES AND DIFFERENT COUNTERMEASURES OF HIV AND SARS-CoV-2  ARVs AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER  PrEP ADHERENCE INTERVENTIONS FOR ADOLESCENTS AND YOUNG ADULTS Eric O. Freed Moherndran Archary Sybil Hosek  IMMUNE RESPONSES TO SARS-CoV-2  GOT ANYTHING FOR THIS COUGH? NEW ANTIVIRALS FOR TREATMENT OF SARS-CoV-2  IMPROVING HOW WE MARKET PrEP TO YOUTH Akiko Iwasaki Davey M. Smith Elzette Rousseau S-3 TUBERCULOSIS: NEW APPROACHES TO PREVENTION AND TREATMENT AND ISSUES FOR PREGNANT WOMEN AND S - 7 COVID -19: FAR MORE THAN JUST THE LUNGS S-11 FOCUS ON THE LIVER: NEW INSIGHTS INTO MANAGEMENT AND CONTROL OF LIVER DISEASE CHILDREN Conveners: Serena S. Spudich and Peter Reiss Conveners: David L. Thomas and Jürgen K. Rockstroh Conveners: Constance A. Benson and Richard E. Chaisson  SINGLE VASCULAR CELL HETEROGENEITY IN HEALTH AND DISEASE: A COVID-19 UPDATE  HEPATITIS C ELIMINATION: WHAT'S TAKING SO LONG?  THE POTENTIAL OF LONG-ACTING INJECTABLE DRUGS FOR PREVENTION AND TREATMENT OF TUBERCULOSIS Peter Carmeliet Annie Luetkemeyer Eric Nuermberger  BODY ON FIRE: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN  MECHANISMS AND TREATMENTS OF STEATOSIS IN HIV  PREGNANCY, HIV, AND TUBERCULOSIS: CURRENT PRACTICES AND RESEARCH OPPORTUNITIES Elizabeth A. Whittaker Steven Grinspoon Jyoti S. Mathad  THINK ABOUT IT: NEUROLOGIC MANIFESTATIONS OF COVID-19  HARNESSING IMMUNITY TO CURE HBV  ADVANCES IN PEDIATRIC TUBERCULOSIS PREVENTION AND TREATMENT Benedict D. Michael Ulrike Protzer Nicole Salazar-Austin  COVID-19: CONCERNS OF THE HEART  NEW PROSPECTS FOR THE TREATMENT OF HBV  IMPACT OF COVID-19 PANDEMIC ON HIV AND TUBERCULOSIS: WHO PERSPECTIVE Valentina O. Puntmann Heiner Wedemeyer Souyma Swaminathan S-8 WHAT DOES PrEP DELIVER? S-12 COVID-19 VACCINE: FROM EFFICACY TO EFFECTIVENESS S-4 EFFECT OF HIV ON COVID, EFFECT OF COVID ON HIV Conveners: Connie L. Celum and Monica Gandhi Conveners: Susan P. Buchbinder and Carlos del Rio Conveners: François Dabis and Wafaa M. El-Sadr  YOUNG WOMEN: ADHERENCE, EFFECT, AND RETENTION  LESSONS LEARNED AND CHALLENGES IN COVID-19 VACCINE TRIALS  DOES HIV IMPACT COVID-19 SUSCEPTIBILITY OR SEVERITY? Thesla Palanee-Phillips Kathleen Neuzil Julia Del Amo  CHALLENGES AND OPPORTUNITIES IN IMPLEMENTING PrEP IN KEY POPULATIONS  EQUITABLE ROLL-OUT OF COVID-19 VACCINES IN THE UNITED STATES  THE IMPACT OF COVID-19 ON THE HIV PANDEMIC WORLDWIDE Gregorio A. Millett Michelle A. Williams Andrew D. Kambugu  MODELS OF DELIVERING PrEP IN EAST AFRICA: INNOVATIONS AND LESSONS LEARNED  VACCINE ACCEPTANCE  THE IMPACT OF COVID-19 BEYOND HIV Moses R. Kamya Saad Omer Helen Bygrave  INCORPORATING INJECTABLE PrEP AND NEWER FORMULATIONS INTO LMIC  GLOBAL DISTRIBUTION OF THE SARS-CoV-2 VACCINE  FEAR AND COVID-19: EXPERIENCES ON THE GROUND Yogan Pillay Nicole Lurie Francois Venter

ALL SCIENCE BASIC SCIENCE (A-F) F-1 NEUROIMAGING AND ASSOCIATED BIOMARKERS I-1 NEW DRUGS, OLD DRUGS, AND NEW RESISTANCE MECHANISMS N-1 WHEN VIRUSES COLLIDE: HIV AND SARS-CoV-2 EPIDEMIOLOGY/PUBLIC HEALTH (R-Y) SPOTLIGHTS™ A-1 VIROLOGY OF SARS-CoV-2 F-2 BIOMARKERS AND NEUROCOGNITIVE STATUS I-2 NEW DEVELOPMENTS IN TRANSMITTED AND ACQUIRED DRUG N-2 SARS-CoV-2: MORE THAN A RESPIRATORY VIRUS R-1 COVID-19 EPIDEMIOLOGY ARE RELEASED A-2 VIROLOGY OF HIV F-3 COMORBIDITIES AND NEUROCOGNITIVE OUTCOMES RESISTANCE O-1 TUBERCULOSIS SCREENING AND DETECTION R-2 HIV EPIDEMIOLOGY ON MARCH 6, B-1 ANIMAL MODELS FOR HIV INFECTION F-4 TREATMENT EFFECTS ON NEUROLOGIC OUTCOMES I-3 NEW RESISTANCE TECHNOLOGIES: ADVANTAGES AND LIMITATIONS O-2 TUBERCULOSIS PREVENTION AND TREATMENT R-3 GEOGRAPHIC AND PHYLOGENETIC TRANSMISSION DYNAMICS 2021, AND ARE B - 2 HOST RESPONSE TO SARS-CoV-2 F-5 CNS RESERVOIRS, ESCAPE, AND CONSEQUENCES J-1 HCV: THERAPEUTICS AND PROGRESS TOWARD ELIMINATION O-3 CRYPTOCOCCAL MENINGITIS DETECTION AND OUTCOMES R-4 DISPARITIES AND STRUCTURAL FACTORS AFFECTING HIV CARE J-2 HEPATITIS B: NO LONGER PLAN B OUTCOMES AVAILABLE B-3 OUTCOMES OF SARS-CoV-2 INFECTION F-6 CNS AND PERIPHERAL NERVOUS SYSTEM: MODELS AND MARKERS OF P-1 MATERNAL VIRAL LOAD AND ART ADHERENCE: INSIGHTS AND B-4 HIV AND THE GUT MICROBIOME PATHOGENESIS J-3 MECHANISMS OF HEPATIC INJURY INTERVENTIONS R-5 STIGMA, MENTAL HEALTH, AND SUBSTANCE USE: IMPACT ON THROUGHOUT B-5 NATURAL CONTROL OF HIV INFECTION J-4 HEPATITIS A AND D P-2 CHRONIC COMORBIDITIES IN PREGNANT WOMEN WITH HIV OUTCOMES THE B-6 HOST EFFECTS ON HIV INFECTION CLINICAL (G-Q) J-5 HEPATITIS AND LIVER TRANSPLANTATION P-3 UNDERSTANDING AND IMPROVING PREGNANCY OUTCOMES R-6 MODELING HIV OUTCOMES CONFERENCE B-7 NON T-CELL EFFECTS OF HIV INFECTION G-1 ADVANCES IN ADHERENCE TESTING K1,C1 CANCER: ANAL CANCER AND HPV P-4 EVOLVING INSIGHTS INTO PMTCT SERVICES T-1 RAPID HIV TESTING AND SELF TESTING G-2 EFFECTS OF DRUG DISPOSITION IN THE CSF, LYMPH NODES, LUNG, AND K-2 CANCER: KAPOSI SARCOMA & KAPOSI SARCOMA–ASSOCIATED Q - 1 HEALTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN AND B-8 HIV AND T CELLS T-2 RECENCY ASSAYS AND INCIDENCE ESTIMATION B-9 HIV-CELL INTERACTION IN VIVO GENITAL TRACT HERPESVIRUS, CERVICAL, LUNG, BREAST, LYMPHOMA, AND HEAD & YOUTH T-3 ROUTINE HIV TESTING D-1 EVOLUTION OF ANTIBODY RESPONSES TO SARS-CoV-2 INFECTION G-3 DRUG-DRUG INTERACTIONS: FROM PREDICTIONS TO MANAGEMENT NECK Q-2 CHARACTERIZING THE VIRAL RESERVOIR AND IMMUNE RESPONSE IN D-2 CELLULAR IMMUNE RESPONSES TO SARS-CoV-2 G-4 NEW APPROACHES TO OPTIMIZE DRUG DOSING: LONG ACTING AND K-3 CANCER: RISK, EPIDEMIOLOGY, AND CARE PEDIATRIC HIV INFECTION T-4 SARS-CoV-2 TESTING AND EFFECT OF COVID-19 ON HIV SCREENING D-3 NOVEL VACCINE CONCEPTS BEYOND L-1 BIOMARKERS OF INFLAMMATION, ART, AND ATHEROSCLEROSIS OR Q - 3 ARVs AND bNAbs FOR CHILDREN AND ADOLESCENTS V-1 LESSONS AND CHALLENGES IN ORAL PrEP IMPLEMENTATION D-4 NEUTRALIZING ANTIBODIES DURING INFECTION H-1 NOVEL TREATMENTS FOR SARS-CoV-2: STARTING AT THE BENCH CARDIOVASCULAR DISEASE Q-4 COMPLICATIONS AND MORTALITY IN CHILDREN AND YOUTH V-2 PrEP ADHERENCE AND CONTROL OF STIs H-2 SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS L-2 GLOBAL STUDIES OF CARDIOVASCULAR DISEASE IN HIV Q-5 COVID-19 IN CHILDREN D-5 THE IMPORTANCE OF TISSUE RESIDENCY V-3 NEW PrEP AGENTS AND FORMULATIONS D-6 CHECKING OUT CHECKPOINTS H-3 ANTIRETROVIRAL THERAPY IN THE DEVELOPING WORLD L-3 NOVEL INSIGHTS IN HIV AND CARDIOVASCULAR DISEASE V-4 HIV PREVENTION: CIRCUMCISION AND IDUs E-1 DYNAMICS OF THE HIV RESERVOIR H-4 LONG-ACTING THERAPY: THE TIME HAS COME M-1 WEIGHT GAIN DURING ART X-1 REPRODUCTIVE HEALTH AMONG ADOLESCENTS AT RISK OF HIV E-2 MECHANISMS OF HIV LATENCY H-5 ANTIRETROVIRAL THERAPY: INSIGHTS FROM OBSERVATIONAL STUDIES M-2 TYPE 2 DIABETES DURING ART E-3 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL H-6 CLINICAL TRIALS OF ANTIRETROVIRAL THERAPY: TREATMENT NAIVE M-3 EPIDEMIOLOGY OF COMORBIDITIES X-2 EPIDEMIOLOGY OF SYPHILIS AND HIV COINFECTION: THE MORE THINGS CHANGE… REBOUND AND SWITCH M-4 INFLAMMATION AND COMORBIDITIES DURING ART E-4 HIV RESERVOIRS IN CELLS AND TISSUES M-5 FRAILTY AND FUNCTIONAL STATUS X-3 ISSUES IN HIV AND WOMEN'S REPRODUCTIVE HEALTH E-5 CONTROLLERS AND POSTTREATMENT CONTROLLERS M-6 RENAL AND BONE DISEASES Y-1 EFFECT OF COVID-19 ON HIV SERVICES E-6 ASSAYS TO MEASURE AND CHARACTERIZE HIV PERSISTENCE Y-2 THE HIV CARE CASCADE E-6 ASSAYS TO MEASURE AND CHARACTERIZE HIV PERSISTENCE Y-3 DIFFERENTIATED SERVICE DELIVERY Y-4 PREEXPOSURE PROPHYLAXIS Y-5 KEY POPULATIONS

ON-DEMAND PROGRAM Last Updated on March 4, 2021